Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPX638 for analgesia in painful wounds
ACTRN12617001629325Phase 2Completed
- Sponsor
- Vapogenix
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sevoflurane in wound pain, sponsored by Vapogenix. Primary endpoint: Analgesic effect during wound care procedure. Started Dec 2017; status: completed.
02
Drugs
sevoflurane
03
Conditions
wound pain
Beyond the preview
Go deeper on ACTRN12617001629325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001629325.